Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Doses of CVN766 in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CVN 766 (Primary)
Indications Psychiatric disorders
Focus Adverse reactions
Sponsors Cerevance

Most Recent Events

16 May 2023 According to a Cerevance media release, today announced company plans to present data for the first time from this trial at an oral presentation at the upcoming American Society of Clinical Psychopharmacology (ASCP) conference, taking place in Miami, Florida, May 30 - June 2, 2023.
09 Jan 2023 Results published in a Cerevance media release.
21 Nov 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com